Prolonged Exposure Therapy for PTSD in Pregnant Patients
This study is looking at a treatment called prolonged exposure therapy + incentives (PE+) for pregnant women with Posttraumatic Stress Disorder (PTSD). PE+ is a type of talk therapy that helps people process traumatic memories. The study wants to see if PE+ can reduce PTSD symptoms in pregnant patients. You might be able to join if you are a woman over 18, are 25 weeks pregnant or less, and have been diagnosed with PTSD. If you are taking psychiatric medications, your dose must have been stable for at least 14 days. All 30 participants will receive PE+ therapy for 12 weeks. The main goal is to see how much PTSD symptoms change from the beginning to the end of the 12 weeks.
- Study design
- This is an interventional study planning to enroll 30 participants. All participants will receive the same treatment, prolonged exposure therapy + incentives.
- What's involved
- You would receive individual PE+ therapy for 1 hour weekly for 12 weeks. You would also attend assessment visits every 4 weeks for 12 weeks and allow medical record collection after delivery.
- Compensation
- You will receive financial incentives for attending each PE+ session.
- Follow-up
- Your PTSD symptoms will be measured from the start of the study up to the 12-week assessment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in Posttraumatic Stress Disorder Symptom Severity - Clinician RatedFrom baseline to the 12-week assessment
Change in posttraumatic stress disorder symptom severity as measured by Clinician Administered PTSD Scale (CAPS-5) for clinician-rated posttraumatic stress symptoms. The CAPS-5 is a 30-item structured interview. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 PTSD symptoms, each with severity scores ranging from 0-4. The overall total severity score for CAPS-5 ranges from 0-80, with lower scores representing better outcomes (less severe PTSD).
- Acceptability of prolonged exposure therapy + incentives for therapy session attendanceFrom baseline to the 12-week assessment
Change in treatment acceptability as measured by the Treatment Acceptability/Adherence Scale (TAAS). The TAAS is a 10-item scale, each with a range of 1-7 and some of which are reverse-scored. The total TAAS score is calculated by summing the score for the 10 TAAS items and the overall TAAS score ranges from 10-70, with higher scores representing better outcomes (greater treatment acceptability).